SAN FRANCISCO – Thermo Fisher Scientific Inc. has entered an agreement with Illumina Inc. for DNA and RNA sequencing technology, and will continue to integrate its newest acquisition, Patheon, this year. Fisher also plans to launch a comprehensive clinical mass spectrometry, executives reported at the J.P. Morgan Healthcare Conference.

SAN FRANCISCO – Medtronic plc and Abbott Laboratories both reported a positive outlook and anticipated growth expected in 2018, following on payoffs from long-term strategy at the J.P. Morgan Healthcare Conference. Acquisitions and divestures were expected to add to the bottom line in the coming months, executive teams shared.